Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DATE study of immediate durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC
jRCTs031190117Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: 1-year progression-free survival rate. Started Feb 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031190117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190117.